智通财经APP讯，长风药业(02652)发布公告，于2025年11月25日，公司董事会已考虑及批准建议实施公 司20名股东持有的公司1.07亿股非上市内资股转换为公司H股，占公司于本公告日期已发行股本总额约 26.1%。申请H股全流通的非上市内资股数目尚需向中国证监会备案。 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 1 在取得所有相關批准（包括向中國證監會備案）及遵守所有適用法律、規則及法規 後，有關非上市內資股將轉換為本公司H股。本公司將向聯交所申請該等H股於聯 交所主板上市及買賣（「轉換及上市」）。根據本公司之公司章程，毋須於股東大會 上取得本公司股東進一步批准以批准轉換及上市。 於本公告日期，本公司尚未向中國證監會提交H股全流通的申請文件。本公司將 根據上市規則及適用法律法規的規定適時就H股全流通以及轉換及上市的進展作 出進一步公告。 H股全流通以及轉換及上市須遵守中國證監會、聯交所及其他境內外監管機 構規定的其他相關程序。本公司股東及潛在投資者於買賣本公司證券時務請 審慎行事。 內幕消息 本公司建議實施H股全流通 本公告乃由長風藥業股份有限公司（「本公司」連同其附屬公司統稱為「本集 ...

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced that its board has approved a resolution regarding the proposal to grant the directors a general mandate to repurchase the company's issued H shares listed on the Main Board of the Hong Kong Stock Exchange [1] Group 1 - The proposal will be presented to the company's shareholders for consideration and approval at a special general meeting to be held at an appropriate time [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced that its board has reviewed and approved a proposal to grant general authority for the repurchase of its issued H shares listed on the Main Board of the Hong Kong Stock Exchange, which will be presented for consideration and approval at a special general meeting of shareholders to be held at an appropriate time [1] Group 1 - The board of Changfeng Pharmaceutical has approved a resolution regarding the repurchase of H shares [1] - The proposal will be submitted for shareholder approval at a special general meeting [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced a proposal to adopt a H-share incentive trust plan for 2025, aimed at aligning the interests of employees, management, and shareholders, while attracting, retaining, and motivating key talent to drive the company's sustainable development and long-term success [1] Summary by Relevant Categories - **Incentive Plan** - The H-share incentive plan is designed to align the interests of employees, management, and shareholders [1] - The plan aims to attract, retain, and motivate key talent within the company [1] - It is intended to reward contributions from employees and management, promoting the company's ongoing development [1] - **Long-term Strategy** - The initiative is part of the company's strategy to ensure sustainable growth and long-term success [1] - By implementing this plan, the company seeks to enhance its competitive position in the industry [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced a proposal to adopt a H-share incentive trust plan on November 12, 2025, aimed at aligning the interests of employees, management, and shareholders, while attracting, retaining, and incentivizing key talents to drive the company's sustainable development and long-term success [1] Group 1 - The H-share incentive plan is designed to align the interests of employees, management, and shareholders [1] - The plan aims to attract, retain, and incentivize key talents within the company [1] - The initiative is expected to contribute to the company's sustainable development and long-term success [1]

Core Viewpoint - Changfeng Pharmaceutical (02652.HK) has announced the adoption of the H-share incentive trust plan aimed at aligning the interests of employees, management, and shareholders, thereby attracting, retaining, and motivating key talents to drive the company's sustainable development and long-term success [1] Group 1 - The H-share incentive plan is set to be implemented on November 12, 2025 [1] - The primary goal of the plan is to ensure the alignment of interests among employees, management, and shareholders [1] - The initiative is designed to attract, retain, and motivate key talents while rewarding their contributions [1]

Core Viewpoint - Changfeng Pharmaceutical (02652.HK) has announced that its board of directors has approved a proposal to grant a general mandate for the repurchase of the company's issued H shares listed on the Hong Kong Stock Exchange, which will be presented for consideration and approval at a forthcoming special general meeting of shareholders [1] Group 1 - The board's resolution includes a proposal for a share buyback authorization [1] - The proposal will be submitted to shareholders for approval at a special general meeting [1]

CF PharmTech, Inc. 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 承董事會命 長風藥業股份有限公司 董事長、執行董事兼首席執行官 自願性公告 建議股份購回授權 本公告乃由長風藥業股份有限公司（「本公司」）自願作出。 本公司董事（「董事」）會（「董事會」）宣佈，董事會已審議並批准一項有關建議授 予董事購回本公司於香港聯合交易所有限公司（「聯交所」）主板上市的已發行H股 的一般授權（「股份購回授權」）的決議案。該建議將於本公司擬適時舉行之股東特 別大會（「股東特別大會」）上提呈予本公司股東考慮及批准。 聯交所證券上市規則規定的有關建議股份購回授權的說明函件將載於股東特別大 會通函。說明函件將載有一切合理所需資料，以使本公司股東於股東特別大會上 就投票贊成或反對有關股份購回授權的決議案作出知情決定。 梁文青博士 香港，2025年11月13日 於本公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 建議採納H股獎勵計劃 建議授權董事會及╱或授權人士 辦理H股獎勵計劃相關事宜 建議採納H股獎勵計劃 長風藥業股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，於2025 年11月12日，其已決議建議採納本公司2025年H股獎勵信託計劃（「H股獎勵計 劃」）。 H股獎勵計劃旨在使本公司僱員、管理層及股東（「股東」）的利益趨於一致，吸 引、挽留並激勵關鍵人才，回報其貢獻，推動本公司持續發展及長遠成功。 H股獎勵計劃構成香港聯合交易所有限公司證券上市規則（「上市規則」）第17章項 下所提述之涉及本公司現有股份之計劃，且須遵守上市規則第17.12條項下之適 用披露規定。然而，H股獎勵計劃並不涉及根據上市規則第17章發行新股份或授 出本公司任何新證券之購股權。因此，根據上市規則，採納該計劃毋須經股東批 准。儘管如此，根據本公司之公司章程，H ...